Diabetes
Conference Coverage
CONCLUDE data inconclusive on hypoglycemia risk for degludec vs. glargine
BARCELONA – The primary endpoint of the study was not met, thus differences between the long-acting insulins could not be confirmed.
Conference Coverage
Machine learning–derived risk score predicts heart failure risk in diabetes patients
Highest WATCH-DM scores linked to 5-year heart failure risk approaching 20%.
Conference Coverage
Semaglutide beats canagliflozin as second-line therapy for type 2 diabetes
BARCELONA –
News from the FDA/CDC
FDA approves oral semaglutide for HbA1c management in type 2 diabetes
It is the first glucagonlike peptide–1 receptor agonist treatment in pill form for this condition.
Conference Coverage
First data VERIFY value of early combination therapy in type 2 diabetes
BARCELONA –
News
Dapagliflozin given Fast Track status for HF therapy
The designation is for reduction of cardiovascular death risk or disease progression in patients with reduced or preserved ejection fraction.
Latest News
NICE issues recommendation for dapagliflozin-insulin therapy in type 1 diabetes
The
Video
DAPA-HF results transform dapagliflozin from antidiabetic to heart failure drug
Conference Coverage
Weight loss surgery linked to lower CV event risk in diabetes
Metabolic surgery was associated with a significantly lower cumulative incidence of myocardial infarction, ischemic stroke, and mortality than...
Conference Coverage
Ticagrelor: Modest benefit, bigger bleed risk in diabetes plus stable CAD
Patients with prior PCI fared a bit better and may be a target population for long-term DAPT therapy.
From the Journals
Higher BMD linked to family history of diabetes in postmenopausal women
The connection may be related to insulin resistance.